tradingkey.logo

Bristol Myers Squibb Receives European Commission Approval For Perioperative Regimen Of Neoadjuvant Opdivo(Nivolumab) And Chemotherapy Followed By Adjuvant Opdivo For Resectable, High-Risk Non-Small Cell Lung Cancer With Pd-L1 Expression ≥1%

ReutersMay 16, 2025 11:31 AM

- Bristol-Myers Squibb Co BMY.N:

  • BRISTOL MYERS SQUIBB RECEIVES EUROPEAN COMMISSION APPROVAL FOR PERIOPERATIVE REGIMEN OF NEOADJUVANT OPDIVO® (NIVOLUMAB) AND CHEMOTHERAPY FOLLOWED BY ADJUVANT OPDIVO FOR RESECTABLE, HIGH-RISK NON-SMALL CELL LUNG CANCER WITH PD-L1 EXPRESSION ≥1%

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI